The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart disease, Parkinson’s, sleep apnea and addiction.

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests.

About 4,500 patients who took semaglutide, sold under the brands Ozempic and Wegovy, had the lowest risk of hospitalization. Another 2,500 who took liraglutide, marketed as Victoza and Saxenda, had the second lowest risk. And there was another notable finding.

The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require hospitalization, new research shows. Numerous studies had already hinted that semaglutide might act on appetite centers in the brain to suppress the urge to drink,